Oxford Biomedica Signs a Five-Year Agreement with the Vaccines Manufacturing and Innovation Centre (VMIC) for (VMIC)
Shots:
- Oxford Biomedica and VMIC entered into a five-year agreement for the manufacturing of adenovirus vector-based COVID-19 vaccine- AZD1222 for scaling up the production of the vaccine from the summer of 2020 to meet the demand in UK and EU
- VMIC will provide manufacturing equipment whereas Oxford Biomedica will provide training and technical assistance to VMIC staff to accelerate the GMP manufacturing capabilities for AZD1222 at VMIC’s Harwell Science and Innovation Campus’ manufacturing site- expected to open in mid-2021
- On May 28- 2020- AstraZeneca got global manufacturing- development and distribution responsibilities for AZD1222 from Oxford Biomedica under a clinical and commercial supply agreement
Click here to read full press release/ article | Ref: Oxford Biomedica | Image: Twitter
Related News: Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
